hepatitis C | oncology | Anadys Pharmaceuticals, Inc.

7/30/2010
Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference

7/29/2010
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24

7/29/2010
Anadys Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights

Anadys at the EASL Annual Meeting, Vienna, Austria, April 14-18, 2010
(not a webcast event)

Late-breaker poster presentation on ANA598 Phase II data: April 15, 2010
Poster presentation on ANA598 preclinical data: April 16, 2010

Anadys at the BofA Healthcare Conf, New York
May 11-13, 2010

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.		ANA598 - HCV ANA773 - HCV ANA773 - Oncology
Home \| About Us \| Therapeutic Focus \| Development Programs \| Investors \| Careers \| Contact Us Terms of Use \| Privacy Policy \| Site Map © Anadys Pharmaceuticals, Inc.